流感疫苗市场预计到2032年价值227.1亿美元-动脉网

Influenza Vaccine Market is Forecasted to Worth US$ 22.71 Billion By 2032

BioSpace 等信源发布 2024-04-29 09:37



可切换为仅中文







The global influenza vaccine market was valued at US$ 8.78 billion in 2023. The global market is projected to hit the market valuation of US$ 22.71 billion by 2032, growing at a CAGR of 11.07% during the forecast period from 2024 to 2032.

2023年，全球流感疫苗市场价值87.8亿美元。预计到2032年，全球市场的市值将达到227.1亿美元，在2024年至2032年的预测期内，复合年增长率将达到11.07%。

The influenza vaccine market continues to thrive, supported by strong government backing and partnerships with local stakeholders, leading to significant growth. Furthermore, the increasing prevalence of seasonal flu contributes to the overall demand for the vaccine. The Asia Pacific region presents attractive revenue prospects due to limited consumer awareness and availability..

在强有力的政府支持和与当地利益相关者的合作伙伴关系的支持下，流感疫苗市场继续繁荣，导致了显着的增长。此外，季节性流感的日益流行有助于对疫苗的总体需求。由于消费者意识和可用性有限，亚太地区呈现出诱人的收入前景。。

The influenza vaccine market is experiencing notable expansion, with flu vaccines exhibiting different levels of effectiveness, yet all providing valuable protection. The CDC advises that individuals aged 6 months and above should receive the flu vaccine every flu season. Children aged 6 months to 8 years might require 2 doses within one flu season, while everyone else only needs 1 dose per season.

流感疫苗市场正在经历显着的扩张，流感疫苗表现出不同程度的有效性，但都提供了有价值的保护。疾病预防控制中心建议，6个月及以上的人应在每个流感季节接种流感疫苗。6个月至8岁的儿童可能需要在一个流感季节内服用2剂，而其他人每个季节只需要服用1剂。

The CDC projects that each dose can lower the risk by 40 to 60%, highlighting the ongoing necessity for new vaccines as the flu virus evolves..

疾病预防控制中心预计，每剂疫苗都可以将风险降低40%至60%，这突显了随着流感病毒的发展，新疫苗的持续必要性。。

Get report sample pages@ https://www.astuteanalytica.com/request-sample/influenza-vaccine-market

获取报表示例页@https://www.astuteanalytica.com/request-sample/influenza-vaccine-market

According to a study by the World Health Organization (WHO), the demand for seasonal influenza vaccines is stable and primarily concentrated in high- and upper-middle-income countries, which account for over 95% of the consumption of these vaccines. Surprisingly, only 27 countries organized into low- or lower-middle-income categories reported having a vaccination policy for seasonal influenza.

根据世界卫生组织（WHO）的一项研究，季节性流感疫苗的需求稳定，主要集中在高收入和中上收入国家，占这些疫苗消费量的95%以上。令人惊讶的是，只有27个中低收入国家报告有季节性流感疫苗接种政策。

The study forecasts a potential increase in demand for these vaccines by approximately 10% over the next 10 years. Notably, there is significant potential to enhance the use of these vaccines, particularly in lower-middle and low-income countries. Furthermore, the development of numerous vaccines with potential improvements over existing ones is expected to drive market growth during the forecast period. .

该研究预测，未来10年对这些疫苗的需求可能会增加约10%。值得注意的是，加强这些疫苗的使用具有巨大潜力，特别是在中低收入国家。此外，预计在预测期内，许多疫苗的开发以及对现有疫苗的潜在改进将推动市场增长。。

Government Support Promoting the Influenza Vaccine Market Growth

政府支持促进流感疫苗市场增长

The increased awareness and government intervention are crucial factors driving the market, highlighting the pressing and expanding need for effective influenza vaccination strategies on a global scale. For instance, in October 2023, the Health Department in Hong Kong introduced the Seasonal Influenza Vaccination Subsidy Scheme (VSS) for the 2023/24 season.

提高认识和政府干预是推动市场的关键因素，突显了在全球范围内迫切需要有效的流感疫苗接种策略。例如，2023年10月，香港卫生署推出了2023/24季节季节性流感疫苗接种补贴计划（VSS）。

This program offers subsidized seasonal influenza and pneumococcal vaccination to eligible Hong Kong residents through the participation of private doctors..

该计划通过私人医生的参与，为符合条件的香港居民提供补贴的季节性流感和肺炎球菌疫苗接种。。

The presence and extent of national policies governing influenza vaccine usage vary significantly. For instance, as of November 2023, 123 (63%) countries have reported having an influenza vaccination policy through the WHO/UNICEF Joint Reporting Form (JRF). This includes 96 (85%) countries categorized by the World Bank as high- (HIC) or upper-middle-income countries (UMIC). .

控制流感疫苗使用的国家政策的存在和程度差异很大。例如，截至2023年11月，123个（63%）国家通过世卫组织/联合国儿童基金会联合报告表（JRF）报告了流感疫苗接种政策。其中包括96个（85%）被世界银行归类为高（HIC）或中上收入国家（UMIC）的国家。。

Among countries with a policy, 74 (60%) recommend vaccinating all WHO priority groups, while 41 countries (33%) have policies that go beyond WHO recommendations to encompass the entire population.

在有政策的国家中，74个（60%）建议为世卫组织所有优先群体接种疫苗，而41个国家（33%）的政策超出了世卫组织的建议，涵盖了整个人口。

Conversely, only 27 (34%) of low- (LIC) and lower-middle-income countries (LMIC) have a policy recommendation to support public financing, procurement, or use of seasonal influenza vaccines, highlighting the unequal utilization of these vaccines in different income groups and thus presenting an opportunity for demand growth..

相反，只有27个（34%）的低收入国家和中低收入国家（LMIC）提出了支持公共融资，采购或使用季节性流感疫苗的政策建议，突出了这些疫苗在不同收入群体中的不平等使用，从而为需求增长提供了机会。。

Production, Supply, and Consumption: An Analysis of Global Influenza Vaccine

生产、供应和消费：全球流感疫苗分析

Influenza vaccine production, supply, and consumption are crucial for public health strategies to combat the impact of influenza viruses on global populations. The analysis of these aspects involves understanding the current production capacity, limitations, and challenges associated with the supply chain, as well as the efforts to improve vaccine effectiveness and distribution..

流感疫苗的生产，供应和消费对于公共卫生战略至关重要，以应对流感病毒对全球人口的影响。对这些方面的分析涉及了解与供应链相关的当前生产能力，局限性和挑战，以及提高疫苗有效性和分销的努力。。

According to a study published by the World Health Organization (WHO) in 2022, high-income countries (HICs) and upper-middle-income countries (UMICs) consumed 97% of the global seasonal influenza vaccine produced, with 92% of consumption in the Region of the Americas, European Region, and Western Pacific Regions combined.

根据世界卫生组织（WHO）在2022年发表的一项研究，高收入国家（HIC）和中高收入国家（UMIC）消耗了全球生产的季节性流感疫苗的97%，其中92%的消费在美洲地区，欧洲地区和西太平洋地区。

Globally, bulk vaccine is produced by 30 manufacturers, with seven of them responsible for over 85% of the global supply, and the remainder serving primarily local markets. The headquarters of bulk producers are diverse, but 75% are in Europe and Asia..

在全球范围内，散装疫苗由30家制造商生产，其中7家占全球供应量的85%以上，其余主要服务于当地市场。大宗生产商的总部多种多样，但75%位于欧洲和亚洲。。

The global seasonal influenza vaccine programmatic dose requirements (PDR) are projected to total approximately 850 million doses in 2024, representing an increase from historical consumption due to policy changes made in 2022-2023 in high-volume countries, including China. Demand is expected to slowly increase between 2024 and 2034, reaching around 920 million doses by the end of the period, driven by the forecasted growth of the older persons population.

2024年，全球季节性流感疫苗计划剂量要求（PDR）预计将达到约8.5亿剂，这是由于2022-2023年包括中国在内的高产量国家的政策变化而导致的历史消耗量的增加。预计2024年至2034年期间，需求将缓慢增长，到该时期结束时达到约9.2亿剂，这是由老年人口的预测增长所驱动的。

As of November 2023, 29 seasonal influenza vaccines are in clinical development, with 27 considered improved vaccines. Additionally, 21 vaccines are being developed by nine new producers, creating a high likelihood of increasing supply to the market..

截至2023年11月，29种季节性流感疫苗正在临床开发中，其中27种被认为是改进的疫苗。此外，9家新生产商正在开发21种疫苗，这极有可能增加市场供应。。

Ask here for customization study@ https://www.astuteanalytica.com/ask-for-customization/influenza-vaccine-market

在此询问定制研究@https://www.astuteanalytica.com/ask-for-customization/influenza-vaccine-market

Advancement in Production Development: A Major Trend to Watch

生产发展的进步：值得关注的主要趋势

The global influenza vaccine market is experiencing a significant shift in vaccine development, marked by rapid technological advancements. This transformation is leading to a departure from traditional egg-based production methods to embrace cell culture and recombinant DNA technologies. These advancements not only promise faster production times but also potentially greater vaccine effectiveness..

全球流感疫苗市场正在经历疫苗开发的重大转变，其标志是技术的快速进步。这种转变正导致从传统的基于鸡蛋的生产方法转变为拥抱细胞培养和重组DNA技术。这些进步不仅保证了更快的生产时间，而且还可能提高疫苗的有效性。。

According to the analysis of Astute Analytica, the cell culture process is gaining momentum and is projected to grow at the highest Compound Annual Growth Rate (CAGR) of 11.48%. This trend is underscored by significant investments in cell-based vaccine manufacturing. For example, the U.S. Department of Health and Human Services invested over $1 billion in 2019 for the development of cell-based influenza vaccine technology..

根据Astute Analytica的分析，细胞培养过程正在获得动力，预计将以11.48%的最高复合年增长率（CAGR）增长。对基于细胞的疫苗生产的大量投资突显了这一趋势。例如，2019年，美国卫生与公众服务部（U.S.Department of Health and Human Services）投资超过10亿美元用于开发基于细胞的流感疫苗技术。。

Investment in cell culture technology, including government funding and private sector Research and Development (R&D), is significantly contributing to the anticipated growth in this segment. Traditionally, egg-based vaccines take approximately six months to produce, which makes it impossible to respond quickly to fast-mutating influenza viruses..

对细胞培养技术的投资，包括政府资助和私营部门研究与开发（R＆D），对该领域的预期增长做出了重大贡献。传统上，基于鸡蛋的疫苗需要大约六个月的时间才能生产出来，因此不可能对快速突变的流感病毒做出快速反应。。

Sanofi, CSL Seqirus, GSK, and AstraZeneca: Capturing 80% of Share

赛诺菲、中超赛奇鲁斯、葛兰素史克和阿斯利康：获得80%的股份

Sanofi, CSL Seqirus, GSK, and AstraZeneca collectively dominate over 80% of the market share, with Sanofi leading the pack in recent years. In 2022, Sanofi experienced a 2.4% increase in sales, selling 250 million doses of its flu vaccine product line. These industry giants consistently invest in research and development to fortify their positions..

赛诺菲、CSL Sequirus、葛兰素史克和阿斯利康共同占据了80%以上的市场份额，赛诺菲近年来处于领先地位。2022年，赛诺菲的销售额增长了2.4%，销售了2.5亿剂流感疫苗产品线。这些行业巨头不断投资研发以巩固其地位。。

AstraZeneca/MedImmune distinguishes itself by offering an influenza nasal spray. However, Sinovac Biotech and Bharat Biotech have opted to focus on meeting the specific needs of their respective regions rather than expanding globally. Furthermore, the ever-evolving technological landscape presents promising prospects for future competition in the market..

AstraZeneca/Medimune通过提供流感鼻喷雾剂而与众不同。然而，科兴生物科技和巴拉特生物科技选择专注于满足各自地区的具体需求，而不是在全球范围内扩张。此外，不断发展的技术前景为未来的市场竞争提供了广阔的前景。。

Top Players in the Global Influenza Vaccine Market

全球流感疫苗市场的顶尖参与者

Abbott Laboratories

雅培实验室

AstraZeneca

阿斯利康

Emergent BioSolutions Inc

Emergent BioSolutions股份有限公司。

Emergex Vaccines Holding Limited

Emergex疫苗控股有限公司

GSK plc